Core Insights - Jinkai Biotechnology, established on June 8, 2009, went public on August 3, 2023, on the Shenzhen Stock Exchange, focusing on small molecule CDMO services in the global life sciences sector [1] - The company provides custom R&D and production services for small molecule drug intermediates and a limited amount of active pharmaceutical ingredients for global innovative drug manufacturers [1] Financial Performance - For Q3 2025, Jinkai Biotechnology reported revenue of 488 million yuan, ranking 21st among 29 peers, with the industry leader WuXi AppTec at 32.857 billion yuan and the average revenue at 2.547 billion yuan [2] - The net profit for the same period was 103 million yuan, placing the company 11th in the industry, with the top performer WuXi AppTec at 12.206 billion yuan and the industry average at 585 million yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 5.22%, down from 6.33% year-on-year, significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The gross profit margin for the same period was 47.43%, up from 39.11% year-on-year, surpassing the industry average of 37.70%, reflecting robust profitability [3] Executive Compensation - The chairman and CEO, Fumin Wang, received a salary of 3.2117 million yuan in 2024, an increase of 225,900 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.48% to 14,100, while the average number of circulating A-shares held per shareholder increased by 1.50% to 4,027.61 [5]
金凯生科的前世今生：2025年Q3营收4.88亿低于行业均值，净利润1.03亿高于行业中位数